GENNIEFY
Market News
Latest financial news and analysis from global markets
GOOGL
These Stocks Are Today’s Movers: Qualcomm, Microsoft, Alphabet, Amazon, Meta, Quanta Services, Hertz, Caterpillar, Ford, and More
Alphabet rises after the Google parent reports strong first-quarter earnings, while Meta sinks on lofty capital spending guidance.
CAT
These Stocks Are Today’s Movers: Qualcomm, Microsoft, Alphabet, Amazon, Meta, Quanta Services, Hertz, Caterpillar, Ford, and More
Alphabet rises after the Google parent reports strong first-quarter earnings, while Meta sinks on lofty capital spending guidance.
PFE
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%
Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.
AAPL
Qualcomm's Handset Growth Remains Major Challenge, Morgan Stanley Says
Qualcomm (QCOM) guided for handset volume below seasonal demand for the second consecutive quarter,
PLTR
Oppenheimer Initiates Palantir With Outperform and $200 Price Target: Is the AI Application Leader Worth the Premium?
On April 30, Oppenheimer initiated coverage of Palantir (NASDAQ:PLTR) stock with an Outperform rating and a $200 price target. The bullish call rests on Palantir’s Ontology-anchored architecture, which the firm believes creates considerable switching costs once embedded, alongside defense technology tailwinds and rapid commercial expansion. For long-term investors, the initiation lands as a fresh institutional ... Oppenheimer Initiates Palantir With Outperform and $200 Price Target: Is the AI Ap
ETHUSDT
Another Day Brings Another Crypto Hack, Wasabi Protocol Drained for $5M+
April 2026 now ranks as the most-hacked month in crypto history, by number of incidents.
BMY
Thinning revenues: inside the $14bn Eliquis patent cliff
With $14.bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
PFE
Thinning revenues: inside the $14bn Eliquis patent cliff
With $14.bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
NKE
Nike Stock Looks Cheap. But Is It?
Nike stock has fallen sharply, but it's not necessarily a bargain.
INTC
Nike Stock Looks Cheap. But Is It?
Nike stock has fallen sharply, but it's not necessarily a bargain.
ABT
How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0
Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that integrates high‑resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions. This positions Abbott at the forefront of AI-guided cardiovascular care, potentially making OCT a more intuitive, workflow-friendly tool for treating challenging coronary disease cases. Next, we’ll...
MSFT
Elon Musk faces tense questioning in cross-examination by OpenAI's lawyer
By Deepa Seetharaman and Kenrick Cai OAKLAND, California, April 30 (Reuters) - Elon Musk faced tense questioning and showed frustration on the witness stand on Thursday during a second day of cross-